Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus Etalocib in Advanced Pancreatic Cancer
NCT00055250Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC) comparing Gemcitabine + LY293111 with Gemcitabine + Placebo (2 arms). Primary endpoint: 6-month survival. Started Jan 2003; status: completed.
02
Drugs
etalocib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00055250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055250.